These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8723334)

  • 1. Basal ganglia: new therapeutic approaches to Parkinson's disease.
    Graybiel AM
    Curr Biol; 1996 Apr; 6(4):368-71. PubMed ID: 8723334
    [No Abstract]   [Full Text] [Related]  

  • 2. The biochemistry of the basal ganglia and Parkinson's disease.
    Curzon G
    Postgrad Med J; 1977 Dec; 53(626):719-25. PubMed ID: 24209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Basal ganglia disease. Functional neuroanatomy and therapeutic perspectives].
    Ostergaard K; Sunde NA; Dupont E
    Ugeskr Laeger; 2000 Oct; 162(41):5480-3. PubMed ID: 11068522
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Stereotactic microdialysis of the basal ganglia in Parkinson's disease.
    Fedele E; Stanzione P; Stefani A
    J Neurosci Methods; 2013 Jan; 212(2):362. PubMed ID: 23375022
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Stereotactic microdialysis of the basal ganglia in Parkinson's disease. Author reply.
    Dizdar N; Zsigmond P; Kullman A; Dernroth Nezirevic D
    J Neurosci Methods; 2013 Jan; 212(2):363. PubMed ID: 23375023
    [No Abstract]   [Full Text] [Related]  

  • 6. Synaptic plasticity, dopamine and Parkinson's disease: one step ahead.
    Calabresi P; Mercuri NB; Di Filippo M
    Brain; 2009 Feb; 132(Pt 2):285-7. PubMed ID: 19168452
    [No Abstract]   [Full Text] [Related]  

  • 7. [Present status and future prospects for gene therapy in Parkinson's disease].
    Muramatsu S
    Nihon Naika Gakkai Zasshi; 2003 Aug; 92(8):1461-6. PubMed ID: 13677895
    [No Abstract]   [Full Text] [Related]  

  • 8. Why target brain adenosine receptors? A historical perspective.
    Fredholm BB; Svenningsson P
    Parkinsonism Relat Disord; 2020 Nov; 80 Suppl 1():S3-S6. PubMed ID: 33349578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Motor functions of the basal ganglia.
    Wiesendanger M
    Appl Neurophysiol; 1986; 49(5):269-77. PubMed ID: 2889423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic strategies for neurodegenerative disorders: emerging clues from Parkinson's disease.
    Bjarkam CR; Sørensen JC
    Biol Psychiatry; 2004 Aug; 56(4):213-6. PubMed ID: 15312807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
    Strange PG
    Mov Disord; 1993 Jul; 8(3):263-70. PubMed ID: 8101967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of the PAC1 Receptor Expression in the Basal Ganglia of MPTP-Induced Parkinsonian Macaque Monkeys.
    Feher M; Gaszner B; Tamas A; Gil-Martinez AL; Fernandez-Villalba E; Herrero MT; Reglodi D
    Neurotox Res; 2018 May; 33(4):702-715. PubMed ID: 29230633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disorders of the basal ganglia and their modern management.
    Schrag A; Quinn N
    J R Coll Physicians Lond; 1999; 33(4):323-7. PubMed ID: 10472019
    [No Abstract]   [Full Text] [Related]  

  • 14. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
    Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
    Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice.
    González S; Mena MA; Lastres-Becker I; Serrano A; de Yébenes JG; Ramos JA; Fernández-Ruiz J
    Brain Res; 2005 Jun; 1046(1-2):195-206. PubMed ID: 15882845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa delivery systems for the treatment of Parkinson's disease: an overview.
    Goole J; Amighi K
    Int J Pharm; 2009 Oct; 380(1-2):1-15. PubMed ID: 19651197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease.
    Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
    Exp Neurol; 2004 Jul; 188(1):65-73. PubMed ID: 15191803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Harnessing endogenous stem cells to treat neurodegenerative disorders of the basal ganglia.
    Mohapel P; Brundin P
    Parkinsonism Relat Disord; 2004 Jul; 10(5):259-64. PubMed ID: 15196503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the [14C]2-deoxyglucose method.
    Orzi F; Fornai F; Blandini F
    Funct Neurol; 2000; 15(4):269-76. PubMed ID: 11213530
    [No Abstract]   [Full Text] [Related]  

  • 20. Molecular mechanism underlying the cerebral effect of Gly-Pro-Glu tripeptide bound to L-dopa in a Parkinson's animal model.
    Minelli A; Conte C; Cacciatore I; Cornacchia C; Pinnen F
    Amino Acids; 2012 Sep; 43(3):1359-67. PubMed ID: 22218995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.